US Stock MarketDetailed Quotes

CALT Calliditas Therapeutics

Watchlist

38.190
+0.040+0.10%

Close Jul 26 16:00 ET

37.000
-1.190-3.12%

Post 20:01 ET

1.02BMarket Cap-21134P/E (TTM)

Calliditas Therapeutics Stock Forum

2F KILL CHEATERS

May 28 13:23

$Calliditas Therapeutics(CALT.US)$ Bad Demon Trap = Xi Zor Gai 😏

mad541

May 28 12:02

$Calliditas Therapeutics(CALT.US)$ out don't get trapped 😰😰

mad541

May 28 06:54

$Calliditas Therapeutics(CALT.US)$ this is gonna dump on everyone yall misread the pr...🤣🤣 don't get trapped high wait to buyback in 17s

mad541

May 28 05:39

Completion of the offer is conditional upon customary conditions including, amongst other things, Asahi Kasei becoming the owner of more than 90% of the shares in Calliditas (on a fully diluted basis) and receipt of all necessary regulatory approvals.🤣🤣🤣🔻🔻

mad541

May 28 05:39

this was a proposed offer not a offering right now and it was conditional as well no promises smh. 🔻🔻🔻🔻🔻🤣🤣🤣

Jaguar8

Apr 24 03:07

$Calliditas Therapeutics(CALT.US)$
NEWS
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée...

Jaguar8

Apr 18 06:13

$Calliditas Therapeutics(CALT.US)$
NEWS
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon c...

Moomoo AI

Feb 21 00:44

The full approval of TARPEYO by the FDA is seen as a significant achievement for Calliditas, potentially paving the way for future successes. The company's projected revenue growth for 2024 indicates optimism about its financial performance.